Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

America’s largest offshore wind and ocean renewables conference will be held in Virginia Beach, USA next year.

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

A padel version of the Ryder Cup will get underway in 2025 as the rapidly growing sport looks to make the most of its ...